- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
B-cell lymphoma vaccine one step closer to market
Biovest International, a majority owned subsidiary of Accentia Biopharmaceuticals, is announcing that the European Medicines Agency (EMA) has granted the company Small and Medium Sized Enterprise (SME) status. With this status confirmed, Biovest becomes eligible for some specific administrative and economic benefits related to the regulatory process in the European Union regarding their lead oncology product, BiovaxID, the personalized lymphoma vaccine targeting the treatment of certain B-cell subtypes of non-Hodgkin's lymphoma.
Specifically, BiovaxID is believed to be most beneficial as a potential treatment for indolent subtypes of NHL such as follicular lymphoma.
According to Biovest CEO Samuel S. Duffey, "After receiving SME status, the next step in our regulatory strategy is to conduct scientific advice meetings with several national regulatory authorities in the EU."